
Merger Results And Redesignation Of Shares
Share Class of the Company | Number of Consideration Shares to be issued | Merger ratio |
Ventures Shares | 52,389,091 | 0.984075562836560 |
Healthcare Shares | 20,464,086 | 0.868781993057500 |
AIM Shares | 6,592,726 | 2.445551844849200 |
DP67 Shares | 7,191,261 | 0.642528021460783 |
Applications have been made for all the Consideration Shares issued to be admitted to the Official List and to trading on the main market of the London Stock Exchange. It is expected that admission will become effective and that trading will commence at 8.00 a.m. on 18 November 2024. CREST accounts are expected to be credited on 18 November 2024 as well.
Following this allotment but prior to the share Redesignation (described below), the issued share capital of the Company was 257,154,457 ordinary shares and the total number of shares with voting rights in the Company is 257,154,457. The Company does not hold any shares in treasury.
Notwithstanding that this will only be for a short period due to the Redesignation described below, the above figure (257,154,457) can be used by shareholders as the denominator for the calculations by which to determine if they are required to notify their interest in, or a change to, their interest in the Company under the FCA's Disclosure and Transparency Rules.
Pursuant to the Merger, Dr Andrew Mackintosh has today been appointed as a director of the Company.
The unaudited NAV per ordinary share as at 15 November 2024, immediately following the Merger is 42.6p (this being the Merger Value of each ordinary share in the Company).
Share Redesignation
Following the allotment of the Consideration Shares mentioned above, the Company will redesignate 147,531,473 of its issued ordinary shares as deferred shares, which will be immediately repurchased and cancelled, on the basis described in the Circular, in order to re-base the NAV per share of each of ordinary share to £1.00 (the "Redesignation").
The ratio applied in the Redesignation is 0.426292374158617 remaining ordinary shares for every share held prior to the Redesignation and the remaining ordinary shares in the capital of the Company will be subject to a new ISIN number GB00BRBQ0C76. It is expected that admission of the revised ordinary shares post-Redesignation will become effective and that trading will commence on 19 November 2024. CREST accounts are expected to be updated to reflect the Redesignation on 19 November 2024
Following the Redesignation, the issued share capital of the Company will be 109,622,984 ordinary shares and the total number of shares with voting rights in the Company will be 109,622,984. The Company does not hold any shares in treasury.
The above figure (109,622,984) can subsequently be used by shareholders as the denominator for the calculations by which to determine if they are required to notify their interest in, or a change to, their interest in the Company under the FCA's Disclosure and Transparency Rules.
The unaudited NAV per ordinary share as following the Redesignation will be 100p.
END
For further information, please contact:
Company Secretary
Foresight Group LLP
Contact: Stephen Thayer Tel: 0203 667 8100
Investor Relations
Foresight Group LLP
Contact: Andrew James Tel: 0203 667 8181


Legal Disclaimer:
MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.
Comments
No comment